Revaprazan set to drive Yuhan's expansion
05 February 2009
Ian Haydock
Please Login to read the full article.
05 February 2009
Ian Haydock
ian.haydock@informa.com
The South Korean pharmaceutical company Yuhan Corp is looking to expand sales of its novel acid pump antagonist revaprazan into overseas markets as part of an effort to take group revenues past the $1 billion mark over the next few years.
The once-daily product differs from standard proton...
Please Login to read the full article.
RELATED CONTENT
NEWS
- P-CAB molecule moves ahead as Takeda looks to sustain GI franchise
- Price cut hobbles Japan's prescription market in 2010
- AstraZeneca wins EU approval of Axanum for CV prevention in those at gastric risk
- Mirabegron approved in first market as Gardasil and Rotarix also get formal Japanese nod
FEATURES
Other Informa Features
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
